Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis

INTRODUCTION: In patients with inadequate response or intolerance to first biologic disease-modifying antirheumatic drug (bDMARD), guidelines recommend switching to an agent of different mechanism of action or to another bDMARD. However, the reasons behind switching between bDMARD/targeted synthetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Holdsworth, Elizabeth A., Donaghy, Bethany, Fox, Kathleen M., Desai, Pooja, Collier, David H., Furst, Daniel E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572299/
https://www.ncbi.nlm.nih.gov/pubmed/34487340
http://dx.doi.org/10.1007/s40744-021-00357-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572299/
https://www.ncbi.nlm.nih.gov/pubmed/34487340
http://dx.doi.org/10.1007/s40744-021-00357-1

Ejemplares similares